Nymox Pharmaceutical Corp (NYMX) Reports Q1 EPS of $0.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Nymox Pharma (NYMX) Issues Positive Update on NX-1207 Phase 2 in Prostate Cancer
May 13, 2014 9:46 AM EDTNymox Pharmaceutical Corporation (Nasdaq: NYMX) reported positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men... More
